In addition, another meta-analysis by Gandini et al. also demonstrated that PD-L1 expression is significantly associated with mortality and clinical response to anti-PD-1/PD-L1 antibodies in metastatic melanoma patients and with clinical response in patients with non-squamous NSCLC [31]. Here, CD274 is linked to metastatic melanoma.